Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000551403 | SCV000649650 | likely benign | Qualitative or quantitative defects of dysferlin | 2024-12-19 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003144341 | SCV003831325 | uncertain significance | not provided | 2019-04-01 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003144341 | SCV004224925 | uncertain significance | not provided | 2022-10-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004975662 | SCV005571584 | uncertain significance | Inborn genetic diseases | 2024-11-28 | criteria provided, single submitter | clinical testing | The c.3085C>G (p.P1029A) alteration is located in exon 29 (coding exon 29) of the DYSF gene. This alteration results from a C to G substitution at nucleotide position 3085, causing the proline (P) at amino acid position 1029 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001272824 | SCV001455214 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2019-10-28 | no assertion criteria provided | clinical testing |